ArticleThe Journal of clinical investigation2013
Rapamycin, anti-aging, and avoiding the fate of Tithonus.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A complex systems approach to aging biology.Nature aging · 2022Review
- Article
- Is Rapamycin a Dietary Restriction Mimetic?The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Review
- How healthy is the healthspan concept?GeroScience · 2018Article
- The Geropathology Grading Platform demonstrates that mice null for Cu/Zn-superoxide dismutase show accelerated biological aging.GeroScience · 2018Article
- Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders.British journal of clinical pharmacology · 2016Review
- Measures of Healthspan as Indices of Aging in Mice-A Recommendation.The journals of gerontology. Series A, Biological sciences and medical sciences · 2016Article
- The Biology of Aging: Citizen Scientists and Their Pets as a Bridge Between Research on Model Organisms and Human Subjects.Veterinary pathology · 2016Review
- The Role of Autophagy, Mitophagy and Lysosomal Functions in Modulating Bioenergetics and Survival in the Context of Redox and Proteotoxic Damage: Implications for Neurodegenerative Diseases.Aging and disease · 2016Review
- Finding Ponce de Leon's Pill: Challenges in Screening for Anti-Aging Molecules.F1000Research · 2016Review
- How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story.Experimental gerontology · 2015Review
- Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions.Current topics in medicinal chemistry · 2015Review
- Sirtuins: guardians of mammalian healthspan.Trends in genetics : TIG · 2014Review
- eRapa restores a normal life span in a FAP mouse model.Cancer prevention research (Philadelphia, Pa.) · 2014Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
The discovery that rapamycin increased the lifespan of mice was recognized by Science as one of the top 10 scientific breakthroughs of 2009. In addition to increasing lifespan, Neff and colleagues show that while rapamycin improves several functions/pathologies that change with age, it has little effect on the majority of the physiological and structural parameters they evaluated. What do these data tell us about the ability of rapamycin to delay aging and improve quality of life, i.e., prevent the fate of Tithonus?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.